Champions Oncology

07/02/2025

We’ve officially launched our Radiopharmaceutical Services Platform, built for oncology teams advancing radiolabeled therapies.

🧪 Isotopes:
Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211, Tb-161, Cu-64, Zr-89

🧬 In vitro & in vivo workflows

🖥️ Backed by Champions’ Lumin tumor model platform

📄 Learn more: https://hubs.li/Q03vCJbH0

06/30/2025

NOW ENROLLING: Hematological VitroScreen – Ex Vivo Blood Cancer Testing

Unlock the power of your therapeutics with our industry-leading ex vivo platform. The Hematological VitroScreen leverages the largest primary blood cancer model bank (AML, ALL, CLL, MCL, MM), enriched with deep multi‑omic phenotyping, flow cytometry, proteomics, phospho‑proteomics, genomics, and clinical annotations. Fast-track efficacy and mechanism insights to accelerate your preclinical program.

👉 Enroll today: https://hubs.li/Q03vd6Wg0

05/02/2025

🙌Thank You for Joining Us at AACR 2025! 🙌

💡We extend our heartfelt gratitude to everyone who visited Champions Oncology at Booth #839 during the AACR Annual Meeting 2025 in Chicago. It was a pleasure connecting with fellow researchers, clinicians, and industry professionals dedicated to advancing cancer therapies.

📊Throughout the conference, our team presented 15 innovative research posters, showcasing our latest developments in in vivo and ex vivo platforms, as well as clinical specialty testing services designed to accelerate cancer drug development. We were thrilled to engage in meaningful discussions about how our comprehensive oncology services can support your research and clinical trials. We also had the honor of hosting esteemed experts Dr. Shankar Vallabhajosula and Dr. Steffi Oesterreich at our booth, providing attendees with insights into radiochemistry and breast cancer research, respectively.

For those who couldn't attend or wish to revisit our presentations, the posters are now available for download on our website:
👉 https://hubs.li/Q03kQ6b90

🔬💊

04/28/2025

🧬What an amazing day at AACR 2025!

🌍Our team presented four impactful posters that highlight how we're pushing the frontiers of cancer research. We’re proud of the collaboration, innovation, and passion that went into developing platforms and services that are supporting the development of new cancer therapies worldwide.

Today’s poster presentations included:

🔹 #1287: Clinical relevance and translatability of NSCLC patient-derived xenograft (PDX) models for cMET-targeted therapies
🔹 #1228: High throughput phenotyping and drug discovery using TumorGraft3D and flow cytometry
🔹 #1827: Evaluating 177-Lu therapeutics in Castrate Resistant Prostate Cancer PDX Models
🔹 #2849: Mutational signature analysis in TumorGraft PDX bank vs TCGA dataset for better patient modeling

🎯 Download our posters here: https://hubs.li/Q03k6Lx_0

04/28/2025

🚀 BREAKING NEWS! Champions Oncology has been granted a license to use radioactive materials in preclinical studies — a major step forward in advancing radiotherapeutic development.

With this new capability, we’re uniquely positioned to integrate radionuclide-based therapeutic testing with our extensive patient-derived xenograft (PDX) models, driving next-generation radiopharmaceutical innovation.

Read todays Press Release: https://hubs.li/Q03k1YLb0

04/24/2025

✨New Blog Alert ✨Beyond TCGA: TumorGraft’s New Frontier in Cancer Research

Explore how Champions Oncology's TumorGraft® platform is pushing the boundaries of cancer research. In our latest blog, we dive into a compelling case study on mutational signatures that showcases the platform’s unique capabilities.

💡 With over 1,500 patient-derived tumor models across 50+ cancer types, TumorGraft captures the complexity of advanced, metastatic, and heavily treated cancers. By integrating molecular data with detailed pretreatment histories and treatment outcomes, it offers powerful insights into drug response, resistance mechanisms, and personalized therapy development.

📖 Read the full blog to see how Champions' TumorGraft models are transforming oncology research.

Explore how TumorGraft® complements TCGA by providing insights into advanced cancer treatment responses and resistance mechanisms.

04/24/2025

We’re thrilled to announce our new collaboration with Turbine, the pioneers behind the world’s first interpretable cell simulation platform. By integrating our clinically relevant multi-omic datasets with Turbine’s cutting-edge virtual lab, we’re creating a powerful synergy to transform oncology R&D.

Together, we’re accelerating the future of AI-powered cancer research.
Read the Press Release: https://hubs.li/Q03jHpQv0

03/06/2025

📝Our latest blog explores how immunohistochemistry (IHC) and next-generation sequencing (NGS) are revolutionizing ADC development.

Antibody-drug conjugates (ADCs) are changing the landscape of cancer treatment, but predicting their effectiveness remains a challenge. Read our latest blog to learn how Immunohistochemistry (IHC) and Next-Generation Sequencing (NGS) are key to refining patient selection and improving treatment success.

💡 Stay ahead in ADC development—read the full blog here 👉



https://hubs.li/Q039RmtW0

02/18/2025

📢Breaking News: Champions Oncology will be presenting 17 novel research posters at the upcoming 2025 American Association of Cancer Research in April.

These presentations showcase groundbreaking research, highlighting state-of-the-art in vivo and organoid platforms for testing oncology and immuno-oncology drugs. They also introduce AI-powered models that leverage multi-omics datasets to forecast patient outcomes.

Read today's press release: https://hubs.li/Q0377BWL0

02/11/2025

🚨 NOW ENROLLING: Hematological VitroScreen 🚨 Champions' industry-leading ex vivo screening platform for blood cancer therapeutics is now open for enrollment until April 15, 2025! 🌟

Enroll today: https://hubs.li/Q036fvPB0

Champions' Hematological VitroScreen is the industry’s premier ex vivo platform for preclinical evaluation of blood cancer therapies. With the largest living bank of never-passaged, primary blood cancer models, including rare ALL, AML, CLL, MCL, and MM models—this platform provides unmatched biological relevance and insights.

Enroll today to advance your blood cancer research.

02/04/2025

Champions' research supports patients by understanding that each person's cancer experience is unique. On , we stand with all patients around the world in their fight for a cure. Visit https://hubs.li/Q0358D100 to learn more.

01/08/2025

📢BREAKING NEWS: Champions has enhanced our clinical flow cytometry services portfolio by integrating state-of-the-art Cytek Aurora™ instrumentation, facilitating more precise and comprehensive clinical analyses through superior spectral analysis capabilities.

We're also delighted to introduce Troy Tremaine, MBA, who will be leading our bioanalytical commercial strategy. With decades of experience, Troy brings both preclinical and clinical bioanalytical expertise to our already exceptional team.

By adopting this cutting edge technology and strategic leadership, Champions is committed to staying at the forefront of innovation in clinical specialty testing. Learn more in today's Press Release: https://hubs.li/Q031JN1C0